Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(16):1172-1173; doi:10.1093/jnci/dji267
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Zielinski, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zielinski, S. L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

Following Positive Epidemiologic Studies, Statins to Enter Clinical Trials for Cancer Prevention

Sarah L. Zielinski

The first 10% of the full text of this article appears below.

Statins grabbed the headlines earlier this year when several epidemiologic studies produced promising results that the cholesterol-lowering drugs might be associated with reduced risks of several cancers, including breast, colorectal, lung, and prostate cancers. Although some researchers have called for large randomized trials to assess statins' anticancer effects, the drugs will receive their first tests in two smaller phase II trials set to begin later this year.

The first study to receive attention was presented at the annual meeting of the American Association for Cancer Research in April. Using data from the Health Professionals Follow-up Study, Elizabeth Platz, Sc.D., from the Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues found that the use of cholesterol-lowering drugs, mostly statins, was associated with a 46% relative reduction in the risk of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
D. M. Boudreau, E. Koehler, S. J. Rulyak, S. Haneuse, R. Harrison, and M. T. Mandelson
Cardiovascular Medication Use and Risk for Colorectal Cancer
Cancer Epidemiol. Biomarkers Prev., November 1, 2008; 17(11): 3076 - 3080.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
D. M. Boudreau, O. Yu, D. L. Miglioretti, D. S.M. Buist, S. R. Heckbert, and J. R. Daling
Statin Use and Breast Cancer Risk in a Large Population-Based Setting
Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 416 - 421.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Setoguchi, R. J. Glynn, J. Avorn, H. Mogun, and S. Schneeweiss
Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly
Circulation, January 2, 2007; 115(1): 27 - 33.
[Abstract] [Full Text] [PDF]